CD133 mRNA may be a suitable prognostic marker for human breast cancer
Breast cancer is the most commonly malignant cancers in women. CD133 protein is a widely used marker for isolating cancer stem cell (CSC). Its expression is associated with the prognosis of many cancers. However, whether CD133 mRNA could be used as an independent prognostic factor for breast cancer remains inconsistent in previous studies. In this study, I used the Gene Expression-Based Outcome for Breast Cancer Online algorithm (GOBO) software to analysis the prognostic roles of CD133 mRNA in the subtypes of breast cancer. I found that CD133 mRNA is associated with distant metastasis free survival (DMFS) in the patient with all tumors, ER-positive tumors, tamoxifen (TAM) tumors, LN-negative tumors, ER-positive/LN-negative tumors, ER-negative tumors, grade 2 tumors, HER2 enriched tumors, and untreated tumors. These results could provide a molecular target for the subtypes of breast cancer. In this study, I conclude that CD133 mRNA may be a suitable prognostic marker for human breast cancer.